secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001654954-23-004663
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax prioritizes oral levosimendan Phase 3 for PH-HFpEF in 2023
----------------------------------------------------------------

- Company to initiate Phase 3 trial of TNX-103 (oral levosimendan) for PH-HFpEF in 2023.
- PH-HFpEF affects >1.6M North Americans; no FDA-approved therapy exists.
- Patent estate expanded; protection through at least 2040 with additional IP expected in 2023.
- FDA agreed Phase 3 endpoints: 6-minute walk distance at 12 weeks or clinical worsening at 24 weeks.
- Imatinib Phase 3 deferred beyond 2023 pending fundraising and strategic review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423004663/0001654954-23-004663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423004663/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-004663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer